Holen Sie sich die Stockscreener-App
47.49
1.23%
-0.59
Vorhandelsmarkt:
47.39
-0.10
-0.21%
Schlusskurs vom Vortag:
$48.08
Offen:
$47.63
24-Stunden-Volumen:
4.23M
Relative Volume:
1.48
Marktkapitalisierung:
$114.70B
Einnahmen:
$49.41B
Nettoeinkommen (Verlust:
$5.59B
KGV:
18.41
EPS:
2.5789
Netto-Cashflow:
$12.54B
1W Leistung:
+2.79%
1M Leistung:
-0.04%
6M Leistung:
-0.73%
1J Leistung:
-11.23%
1-Tages-Spanne:
$47.42
$48.00
1-Wochen-Bereich:
$46.58
$48.60
52-Wochen-Spanne:
$44.62
$60.12
Sanofi Adr Stock (SNY) Company Profile
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
47.49 | 116.13B | 49.41B | 5.59B | 12.54B | 2.5789 |
|
LLY
Lilly Eli Co
|
1,020.84 | 990.89B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
237.79 | 564.91B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
219.02 | 383.72B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
MRK
Merck Co Inc
|
119.75 | 293.70B | 65.00B | 18.26B | 13.05B | 7.2751 |
|
NVS
Novartis Ag Adr
|
153.95 | 293.40B | 54.72B | 14.02B | 15.32B | 7.1855 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-27 | Eingeleitet | Citigroup | Neutral |
| 2026-01-16 | Herabstufung | UBS | Buy → Neutral |
| 2026-01-06 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-12-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-12-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-09-08 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2025-08-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Outperform |
| 2025-03-21 | Eingeleitet | Goldman | Neutral |
| 2025-01-30 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-07-26 | Bestätigt | Argus | Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2023-12-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-10-30 | Herabstufung | Stifel | Buy → Hold |
| 2023-09-06 | Hochstufung | Berenberg | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-28 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2023-03-27 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2022-12-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-08-12 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2022-08-09 | Herabstufung | UBS | Buy → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Sell |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-03-17 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2020-03-11 | Hochstufung | Goldman | Neutral → Buy |
| 2020-02-11 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-01-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-09-20 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-09-03 | Eingeleitet | Bernstein | Outperform |
| 2019-08-14 | Hochstufung | UBS | Neutral → Buy |
| 2018-12-11 | Hochstufung | Jefferies | Hold → Buy |
| 2018-11-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-09-10 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2018-08-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-03-23 | Hochstufung | Liberum | Hold → Buy |
| 2018-01-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2017-12-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2017-12-01 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2017-11-15 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2017-08-30 | Hochstufung | HSBC Securities | Reduce → Hold |
Alle ansehen
Sanofi Adr Aktie (SNY) Neueste Nachrichten
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS
Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
Sanofi (SNY) Reports Regulatory Win, Barclays Downgrades to 'Equal Weight' with EUR 85 PT - Finviz
The Truth About Sanofi S.A.: Is This ‘Boring’ Pharma Stock a Secret Power Play? - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Regeneron Just Moved From Underperform To Buy - Benzinga
KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? - Finviz
Flu Season's Here-This Dividend-Payer Controls the Shot Market - Finviz
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children - Finviz
REGN Soars 41% in Six Months: Is There More Upside Potential in 2026? - Finviz
Drugmakers Plan Fresh Price Hikes On 350 Medicines In 2026 - Sahm
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Finviz
Where is Sanofi (SNY) Headed According to Wall Street? - Finviz
Delayed MS Decision and Trial Miss Add to Sanofi's R&D Challenges - Finviz
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Finviz
Total debt per share of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView — Track All Markets
Why Dynavax Stock Soared Today - Finviz
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Finviz
Sanofi Makes $2.2 Billion Bet On Adult Vaccines With Dynavax Buy - Sahm
Our Environmental Impact - Sanofi
Bloom Energy Aktie: KI-Boom trifft auf Energiekrise! - Finanztrends
Sanofi (SNY) Shares Under Pressure After JPMorgan and Guggenheim Downgrades - Finviz
Finanzdaten der Sanofi Adr-Aktie (SNY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.08%
2.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):